Results 1 to 10 of about 159,845 (348)

Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial.

JAMA Oncol, 2023
Importance Chronic graft-vs-host disease (GVHD) limits the long-term benefit of haploidentical hematopoietic stem cell transplant (HSCT). This clinical trial evaluated repeated infusions of umbilical cord mesenchymal stem cells (MSCs) during the early ...
Huang R, Chen T, Wang S, Wang J, Su Y, Liu J, Zhang Y, Ma X, Wen Q, Kong P, Zhang C, Gao L, Zhong JF, Gao L, Zhang X.   +14 more
europepmc   +2 more sources

Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation.

JAMA Netw Open, 2023
Key Points Question Are antibiotics and antibiotic exposure timeframes associated with acute graft-vs-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT)?
Rashidi A, Gao F, Fredricks DN, Pergam SA, Mielcarek M, Milano F, Sandmaier BM, Lee SJ.   +7 more
europepmc   +2 more sources

Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease

Frontiers in Immunology, 2019
Graft vs. host disease (GVHD) is the major non-relapse complication associated with allogeneic hematopoietic stem cell transplantation (HSCT). Damage to the gastrointestinal (GI) tract from acute GVHD is a particularly serious event that can result in ...
Clint Piper, William R. Drobyski, William R. Drobyski   +2 more
doaj   +2 more sources

Body Composition Assessment Provides Prognostic Information in Patients With Cancer Affected by Chronic Graft vs. Host Disease [PDF]

Journal of Cachexia, Sarcopenia and Muscle
Background Additional tools are needed to assess mortality risk among patients with cancer. Patients with chronic graft vs. host disease (cGVHD) after allogeneic haematopoietic cell transplantation (HCT) represent a high‐risk cancer population with ...
Asmita Mishra, Ram Thapa, Kevin Bigam, Martine Extermann, Rawan Faramand, Farhad Khimani, Xuefeng Wang, Vickie Baracos, Joseph A. Pidala   +8 more
doaj   +2 more sources

Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance

Frontiers in Immunology, 2019
Graft-vs.-host disease (GVHD) remains a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Hongshuang Yu, Yuanyuan Tian, Ying Wang, Shin Mineishi, Yi Zhang, Yi Zhang   +5 more
doaj   +2 more sources

Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease

Frontiers in Immunology, 2019
Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders.
Govindarajan Thangavelu, Bruce R. Blazar
doaj   +2 more sources

Macrophage regulation of graft-vs-host disease

World Journal of Clinical Cases, 2020
Hematopoietic stem cell transplantation has become a curative choice of many hematopoietic malignancy, but graft-vs-host disease (GVHD) has limited the survival quality and overall survival of hematopoietic stem cell transplantation. Understanding of the
Yaqun Hong, Bo Wan, Xiao-Fan Li
semanticscholar   +3 more sources

The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease

Frontiers in Immunology, 2019
Allogeneic hematopoietic cell transplantation (allo-HCT) is performed with curative intent for high- risk blood cancers and bone marrow failure syndromes; yet the development of acute and chronic graft-vs.-host disease (GVHD) remain preeminent causes of ...
David Bastian, Yongxia Wu, Brian C. Betts, Xue-Zhong Yu, Xue-Zhong Yu   +4 more
doaj   +2 more sources

AAV-mediated expression of HLA-G for the prevention of experimental ocular graft vs. host disease [PDF]

Molecular Therapy: Methods & Clinical Development, 2023
Ocular graft versus host disease (OGvHD) develops after allogeneic hematopoietic stem cell transplantation (HSCT) and manifests as ocular surface inflammatory disease.
Jacob P. Nilles, Darby Roberts, Jacklyn H. Salmon, Liujiang Song, Carly O’Dea, Lindsay T. Marjoram, Jacquelyn J. Bower, Matthew L. Hirsch, Brian C. Gilger   +8 more
doaj   +2 more sources

Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience

Frontiers in Bioengineering and Biotechnology, 2018
The most effective treatment of steroid refractory acute graft vs. host disease (aGvHD) is not yet established and mesenchymal stem cells (MSC) appear to be a promising therapy for the condition. We report single center case series of three patients, who
Maja Česen Mazič, Lenart Girandon, Miomir Kneževič, Simona L. Avčin, Janez Jazbec   +4 more
doaj   +2 more sources